glp-1 ra and Anesthesia: Considerations and Cautions for CRNAs GLP-1 prescription trends through March

64 Overall, GLP-2 appears to be an important regulator of bone metabolism, primarily through inhibiting bone resorption, but with minimal effects on bone formation

Other noteworthy phase 3 trial readouts in 2025 include: Novo Nordisks evoke/evoke+ , investigating oral semaglutide in patients with early Alzheimers disease, potentially expanding the utility of GLP-1s beyond cardiometabolic indications

For specific gene amplification, primers listed in Table 2 were used

Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, et al

Others need a more gradual approach

Read More What are the Side Effects of Beta-Alanine